At a glance
API supply concentration
Exhibit 1China's share of India's API imports
All APIs and bulk drugs, by value
The category on a page
Exhibit 2Where APIs sit
Profit impact against supply risk, R&D subcategories
Exhibit 3India API imports from China
Rs crore
Exhibit 4Antibiotic API price, India
Meropenem, Rs '000 per kg
Typical savings vs spot buying
Contracting at current soft prices, indexed
Value levers
In order of value.
Know the country of every KSM and intermediate, not just the API.
Multi-year indexed contracts while prices are down.
Qualify a second source in another country.
3-6 months for critical, single-country APIs.
Route US-bound patented APIs through EU, UK or onshore sources.
Prefer PLI suppliers for KSMs like PHBA and penicillin-G.
How to buy it
KPIs to track
For the monthly review
Where most buyers are, and what good looks like
| Most buyers today | Best practice | ||
|---|---|---|---|
| Visibility | API supplier only | → | Full KSM origin map |
| Sourcing | Single source | → | Two countries per critical API |
| Pricing | Spot | → | Indexed long-term |
| Stock | Just in time | → | Risk-based safety stock |
| Tariffs | Not tracked | → | Origin and duty modelled |
What AI changes
More in the AI disruption tab.
Full written analysis
Written live for APIs (active ingredients) and your region, grounded on the figures above. Public data only.
Written live for this category and region when the page opens in a browser.
Negotiation playbook
Negotiation playbook
Prices are soft now, but supply is concentrated. Use today's prices to lock indexed contracts, and pay for resilience where a molecule is critical.
Pick the right commercial model
| Indexed multi-year contractUsual best | Price moves with KSM or market index. |
| Fixed annual price | Simple; supplier adds risk premium. |
| Spot buying | Cheap now; exposed to spikes. |
| Consignment safety stock | Supplier holds stock near you. |
Questions to ask suppliers
- Origin
Where are the key starting materials and intermediates for this API made, and by whom?
Good answer: KSM country disclosed. - Index
Will you index the price to a named KSM or market index, both up and down?
Good answer: price follows inputs. - Safety stock
Will you hold three to six months of stock for us, and at whose cost?
Good answer: held for us. - Change notice
How much notice will you give before changing a KSM source or site?
Good answer: early warning. - Tariffs
If US or other tariffs change, how will the cost be split?
Good answer: shared. - Second source
Will you supply documents so we can file a second source quickly?
Good answer: support filing.
Your leverage
- Soft market prices
- Volume across molecules
- Qualified alternatives
- Multi-year commitment
Watch out for
- Price spikes after supply shocks
- Undisclosed KSM changes
- Tariff pass-through without evidence
- Quality shortcuts at low prices
AI disruption
Tailwinds for buyers
- Multi-tier supply mapping.
- Price forecasting from trade data.
- AI route design cuts steps and cost.
- Faster regulatory documents for second sources.
- Quality data analytics.
- Demand forecasting reduces panic buying.
Headwinds for buyers
- Doesn't change China KSM dependence.
- Supplier data quality is poor.
- Trade data lags.
- IP concerns sharing routes.
- Regulatory filing still slow.
- Cyber risk in shared data.
How to capture it
Use AI supply mapping to find single-country KSMs and fund dual sourcing for those first.
Who is changing the market
- Backward integration at Unit 3 lifts margins
- Gives buyers a non-China source for many APIs
- Funds local production of critical KSMs
- Minimum import prices protect new plants
- 20% rate for companies with approved onshoring plans
- Pushes patented API production to the US
Risk radar
Risk radar
Exposure by dimension, 0-100, Global
Risk heat map
Impact against likelihood; numbers match the register below
- US patented API tariff
- China KSM concentration
- Price spikes
- Quality at low prices
Risk register
100% default from Sep 2026.
China 74% of India's API imports.
Prices jumped after West Asia tensions in 2026.
Price cuts can hide shortcuts.
Market pulse
What the biggest suppliers are reporting
From their latest results and investor material.
Q2 FY27. Rs 3,676 cr; custom synthesis +54% (Goldman); about 90% exported, Europe and North America about 75%.
Q2 FY27. CDMO revenue Rs 1,424 cr; FY27 group growth guide raised to 19-20%.
Q3 2026 update (14 Oct). Now a pure-play CDMO; CORE EBITDA margin 33-34%; mid-term ambitions raised.
Q3 2026. 2026 guide raised to RMB 61-61.9bn; backlog RMB 76.7bn; OMB list of 'companies of concern' due by 18 Dec.
Q2 FY27. +13% vs Q1; EBITDA margin 18% vs 22% a year ago; first deal at its US Bayview biologics site; FY27 revenue to fall single digits.
Latest developments
Dated, newest first. Checked 16 Nov 2026.
100%; generics exempt for now.
So what: Check every patented API's origin.
GHY →Paracetamol Rs 250/kg from Rs 600.
So what: Lock indexed contracts now.
India Sea Trade News →Freight and petrochemical costs up.
So what: Hold safety stock for critical APIs.
The Pharma Letter →Up from 68% in FY21 despite PLI.
So what: Map KSMs; fund dual sourcing.
Ministry of Chemicals and Fertilizers (reply to Parliament, Mar 2026) →What this means for your next negotiation
- Prices are soft; lock indexed multi-year contracts now.
- Map KSM origins, not just API suppliers; China is still ~74%.
- Model US tariff exposure for patented APIs now and generics from 2028.
Signals to watch next quarter
Watch renewal for key KSMs.
Could formalise the 2028 tariff.
More local KSM supply.
Sources
- Section 232 tariffs (JD Supra) · Apr 2026
- Section 232 CBP guidance (GHY) · Sep 2026
- Ministry of Chemicals and Fertilizers (reply to Parliament, Mar 2026) · Sep 2026
- India API prices (India Sea Trade News) · Aug 2026
- China API prices (The Pharma Letter) · May 2026
- US pharma tariff and India (India Briefing) · 2026
Figures checked 16 Nov 2026. Tags: Official = published by the source; Derived = calculated from published figures; Judgement = The Procurement Lens view.